Study registration: *
Publication McKeigue P, medRxiv, 2021
Dates: 2020-12-08 to 2021-08-19
Funding: No specific funding (No specific funding was received for this study)
Conflict of interest: Yes (HC receives research support and honoraria and is a member of advisory panels or speaker bureaus for Sanofi Aventis, Regeneron, Novartis, Novo-Nordisk and Eli Lilly. HC receives or has recently received non-binding research support from AstraZeneca and Novo-Nordisk. SH received honoraria from Gilead.)
Methods | |
Study design:Case-control Description of participants: Population of Scotland Inclusion criteria:
Exclusion criteria:
Follow-up duration (months): 8.5 | |
Vaccines: |
|
Variant description : |
|
Variant name: Delta Evidence: Indirect evidence (prevalence of variant in the population: 1 to 99%) | |
Documents available |
Protocol NR Statistical plan NR Data-sharing stated:
Yes, Accessible now |
General comment | Concerns is over uncontrolled confounding: the estimates were not adjusted for socio-economic status, ethnicity or health-seeking behaviour. |